JP2004537546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004537546A5 JP2004537546A5 JP2003513521A JP2003513521A JP2004537546A5 JP 2004537546 A5 JP2004537546 A5 JP 2004537546A5 JP 2003513521 A JP2003513521 A JP 2003513521A JP 2003513521 A JP2003513521 A JP 2003513521A JP 2004537546 A5 JP2004537546 A5 JP 2004537546A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- olanzapine
- lactose
- tartaric acid
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- KVWDHTXUZHCGIO-UHFFFAOYSA-N Olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 5
- 229960005017 olanzapine Drugs 0.000 claims 5
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims 4
- 229960001367 tartaric acid Drugs 0.000 claims 4
- 235000002906 tartaric acid Nutrition 0.000 claims 4
- 239000011975 tartaric acid Substances 0.000 claims 4
- WSVLPVUVIUVCRA-RJMJUYIDSA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;hydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-RJMJUYIDSA-N 0.000 claims 3
- 229960001375 Lactose Drugs 0.000 claims 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims 3
- 229960001021 Lactose Monohydrate Drugs 0.000 claims 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 3
- 239000008101 lactose Substances 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Claims (9)
- オランザピン、酒石酸およびラクトースを含有する製剤。
- ラクトースがラクトース一水和物である、請求項１に記載の製剤。
- オランザピン約１〜約20 mg/ml、ラクトース一水和物約20.0〜50mg/mlおよび酒石酸約0.35〜10 mg/ml含有する製剤。
- オランザピン約１〜約20 mg/ml、ラクトース一水和物約22.5〜50mg/mlおよび酒石酸約0.35〜10 mg/mlを含有する製剤。
- 該製剤が結晶形のオランザピンを含有しない、請求項１に記載の製剤。
- オランザピン、酒石酸およびラクトースを含有する溶液の凍結乾燥を含む、製剤の製造方法。
- 該溶液が水性溶液である、請求項６に記載の方法。
- 該製剤が哺乳動物１匹を処置するために十分な量で容器に入っている、請求項７に記載の方法。
- 活性成分がオランザピンであることを特徴とする、ヒトにおける興奮状態の治療で使用するための請求項１に記載の製剤。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30682901P | 2001-07-20 | 2001-07-20 | |
| US38647402P | 2002-06-07 | 2002-06-07 | |
| PCT/US2002/019799 WO2003007912A2 (en) | 2001-07-20 | 2002-07-05 | Lyophilized formulation comprising olanzapine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004537546A JP2004537546A (ja) | 2004-12-16 |
| JP2004537546A5 true JP2004537546A5 (ja) | 2006-01-05 |
Family
ID=26975390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003513521A Pending JP2004537546A (ja) | 2001-07-20 | 2002-07-05 | ２−メチル−チエノ−ベンゾジアゼピン凍結乾燥製剤 |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US20040176357A1 (ja) |
| EP (1) | EP1423124B1 (ja) |
| JP (1) | JP2004537546A (ja) |
| KR (1) | KR20040017330A (ja) |
| CN (1) | CN1537007A (ja) |
| AR (1) | AR036180A1 (ja) |
| AT (1) | ATE369137T1 (ja) |
| AU (1) | AU2002320134B2 (ja) |
| BR (1) | BR0211250A (ja) |
| CA (1) | CA2448724A1 (ja) |
| CO (1) | CO5540279A2 (ja) |
| CY (1) | CY1107759T1 (ja) |
| CZ (1) | CZ200484A3 (ja) |
| DE (1) | DE60221674T2 (ja) |
| DK (1) | DK1423124T3 (ja) |
| EA (1) | EA006506B1 (ja) |
| ES (1) | ES2289126T3 (ja) |
| HK (1) | HK1066484A1 (ja) |
| HR (1) | HRP20040037A2 (ja) |
| HU (1) | HUP0401157A3 (ja) |
| IL (1) | IL159098A0 (ja) |
| MX (1) | MXPA04000541A (ja) |
| MY (1) | MY135452A (ja) |
| NZ (1) | NZ529667A (ja) |
| PE (1) | PE20030281A1 (ja) |
| PL (1) | PL366614A1 (ja) |
| PT (1) | PT1423124E (ja) |
| SI (1) | SI1423124T1 (ja) |
| SK (1) | SK182004A3 (ja) |
| SV (1) | SV2003001179A (ja) |
| UA (1) | UA80095C2 (ja) |
| WO (1) | WO2003007912A2 (ja) |
| ZA (1) | ZA200400798B (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1575962A1 (en) * | 2002-12-24 | 2005-09-21 | Teva Pharmaceutical Industries Limited | Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms |
| HU226410B1 (en) * | 2003-04-22 | 2008-11-28 | Egis Gyogyszergyar Nyilvanosan | Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them |
| GB0314149D0 (en) * | 2003-06-18 | 2003-07-23 | Generics Uk Ltd | Novel amorphous forms |
| AR047459A1 (es) | 2004-01-27 | 2006-01-18 | Synthon Bv | Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina) |
| WO2006076124A2 (en) * | 2004-12-16 | 2006-07-20 | Nektar Therapeutics | Stable, non-crystalline formulation comprising olanzapine |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US20070293479A1 (en) * | 2006-05-18 | 2007-12-20 | Osinga Niels J | Olanzapine pharmaceutical composition |
| AU2019205329B2 (en) * | 2018-01-05 | 2023-04-20 | Impel Pharmaceuticals Inc. | Intranasal delivery of olanzapine by precision olfactory device |
| HUP2100259A1 (hu) | 2021-07-07 | 2023-01-28 | Richter Gedeon Nyrt | Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények |
| CN115006406A (zh) * | 2021-12-28 | 2022-09-06 | 南京清普生物科技有限公司 | 一种稳定的奥氮平制剂 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69004921T2 (de) * | 1989-09-30 | 1994-05-05 | Eisai Co Ltd | Injizierbare Cephalosporinpräparate und ihre Anwendung. |
| US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
-
2002
- 2002-05-07 UA UA2004010428A patent/UA80095C2/uk unknown
- 2002-07-05 ES ES02749634T patent/ES2289126T3/es not_active Expired - Lifetime
- 2002-07-05 DK DK02749634T patent/DK1423124T3/da active
- 2002-07-05 BR BR0211250-7A patent/BR0211250A/pt not_active IP Right Cessation
- 2002-07-05 CA CA002448724A patent/CA2448724A1/en not_active Abandoned
- 2002-07-05 JP JP2003513521A patent/JP2004537546A/ja active Pending
- 2002-07-05 WO PCT/US2002/019799 patent/WO2003007912A2/en active IP Right Grant
- 2002-07-05 CN CNA028144473A patent/CN1537007A/zh active Pending
- 2002-07-05 PT PT02749634T patent/PT1423124E/pt unknown
- 2002-07-05 AU AU2002320134A patent/AU2002320134B2/en not_active Expired
- 2002-07-05 NZ NZ529667A patent/NZ529667A/en not_active IP Right Cessation
- 2002-07-05 PL PL02366614A patent/PL366614A1/xx not_active Application Discontinuation
- 2002-07-05 CZ CZ200484A patent/CZ200484A3/cs unknown
- 2002-07-05 KR KR10-2004-7000829A patent/KR20040017330A/ko not_active Application Discontinuation
- 2002-07-05 DE DE60221674T patent/DE60221674T2/de not_active Expired - Lifetime
- 2002-07-05 IL IL15909802A patent/IL159098A0/xx unknown
- 2002-07-05 HU HU0401157A patent/HUP0401157A3/hu unknown
- 2002-07-05 SK SK18-2004A patent/SK182004A3/sk unknown
- 2002-07-05 EP EP02749634A patent/EP1423124B1/en not_active Expired - Lifetime
- 2002-07-05 SI SI200230629T patent/SI1423124T1/sl unknown
- 2002-07-05 US US10/480,617 patent/US20040176357A1/en not_active Abandoned
- 2002-07-05 EA EA200400211A patent/EA006506B1/ru not_active IP Right Cessation
- 2002-07-05 AT AT02749634T patent/ATE369137T1/de active
- 2002-07-05 MX MXPA04000541A patent/MXPA04000541A/es active IP Right Grant
- 2002-07-17 PE PE2002000636A patent/PE20030281A1/es active IP Right Grant
- 2002-07-18 AR ARP020102700A patent/AR036180A1/es not_active Application Discontinuation
- 2002-07-18 MY MYPI20022723A patent/MY135452A/en unknown
- 2002-07-19 SV SV2002001179A patent/SV2003001179A/es not_active Application Discontinuation
-
2003
- 2003-12-31 CO CO03113784A patent/CO5540279A2/es not_active Application Discontinuation
-
2004
- 2004-01-15 HR HR20040037A patent/HRP20040037A2/hr not_active Application Discontinuation
- 2004-01-30 ZA ZA2004/00798A patent/ZA200400798B/en unknown
- 2004-12-01 HK HK04109512A patent/HK1066484A1/xx not_active IP Right Cessation
-
2007
- 2007-10-11 CY CY20071101308T patent/CY1107759T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2378424A1 (en) | Moxifloxacin formulation containing common salt | |
| HU9301346D0 (en) | Method and preparative for introducing biologically acive organ into body of living creature | |
| JP2004520290A5 (ja) | ||
| JP2004537546A5 (ja) | ||
| US4831057A (en) | Antisnoring agent | |
| CA2326662A1 (en) | Therapeutic system which can be moisture-activated | |
| PE20010826A1 (es) | Soluciones que contienen epinastina | |
| CA2392050A1 (en) | Pharmaceutical formulations containing zolmitriptan | |
| CA2389292A1 (en) | Absorbent article which maintains prolonged natural skin ph | |
| WO2006138571A3 (en) | Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance | |
| CA2317530A1 (en) | Dysuria remedies | |
| JP2002537232A5 (ja) | ||
| JP2003503453A5 (ja) | ガバペンチンおよびプレガバリンを含む相乗作用組成物 | |
| JP2002537246A5 (ja) | ||
| CO5640085A2 (es) | Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato | |
| MXPA01007210A (es) | Agente para el tratamiento de enfermedad de parkinson que comprende un agente que mejora la funcion del astrocito como ingrediente activo. | |
| JP2005501108A5 (ja) | ||
| EE200200695A (et) | (-)-5-(3-klorofenüül)-alfa-(4-klorofenüül)-alfa-(1-metüül-1H-imidasool-5-üül)tetrasolo -[1,5-a]kinasoliin-7-metaanamiin, selle valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja meetodselle valmistamiseks | |
| JP2003527207A5 (ja) | ||
| JP2001316293A5 (ja) | ||
| DE60032246D1 (de) | Zusammensetzungen, welche tetracycline enthalten, zur behandlung oder verhinderung von mukositis | |
| JP5226956B2 (ja) | インプラント材料 | |
| JP2002501021A5 (ja) | ||
| ES2179729B1 (es) | Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. | |
| WO2001045727A3 (en) | Stabilized veterinary compositions comprising more than one antiviral agent |